249 related articles for article (PubMed ID: 19114973)
1. Neurotoxicity during ifosfamide treatment in children.
Di Cataldo A; Astuto M; Rizzo G; Bertuna G; Russo G; Incorpora G
Med Sci Monit; 2009 Jan; 15(1):CS22-5. PubMed ID: 19114973
[TBL] [Abstract][Full Text] [Related]
2. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
3. Role of thiamine in managing ifosfamide-induced encephalopathy.
Hamadani M; Awan F
J Oncol Pharm Pract; 2006 Dec; 12(4):237-9. PubMed ID: 17156595
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
Bernard PA; McCabe T; Bayliff S; Hayes D
J Oncol Pharm Pract; 2010 Dec; 16(4):262-5. PubMed ID: 20118215
[TBL] [Abstract][Full Text] [Related]
5. Methylene blue for management of Ifosfamide-induced encephalopathy.
Patel PN
Ann Pharmacother; 2006 Feb; 40(2):299-303. PubMed ID: 16391008
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Liu YL; Tsai SH; Chang FW; Yu MH
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide encephalopathy and nonconvulsive status epilepticus.
Primavera A; Audenino D; Cocito L
Can J Neurol Sci; 2002 May; 29(2):180-3. PubMed ID: 12035842
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations.
Kerdudo C; Orbach D; Sarradet JL; Doz F
Pediatr Blood Cancer; 2006 Jul; 47(1):100-2. PubMed ID: 16261598
[TBL] [Abstract][Full Text] [Related]
9. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
Imtiaz S; Muzaffar N
J Pak Med Assoc; 2010 Oct; 60(10):867-9. PubMed ID: 21381624
[TBL] [Abstract][Full Text] [Related]
12. Influence of age upon Ifosfamide-induced nephrotoxicity.
McCune JS; Friedman DL; Schuetze S; Blough D; Magbulos M; Hawkins DS
Pediatr Blood Cancer; 2004 May; 42(5):427-32. PubMed ID: 15049014
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide neuropsychiatric toxicity in patients with cancer.
Alici-Evcimen Y; Breitbart WS
Psychooncology; 2007 Oct; 16(10):956-60. PubMed ID: 17278152
[TBL] [Abstract][Full Text] [Related]
14. Nonconvulsive status epilepticus due to ifosfamide.
Kilickap S; Cakar M; Onal IK; Tufan A; Akoglu H; Aksoy S; Erman M; Tekuzman G
Ann Pharmacother; 2006 Feb; 40(2):332-5. PubMed ID: 16449538
[TBL] [Abstract][Full Text] [Related]
15. Progress in the development of childhood cancer therapy.
Garolla A; Pizzato C; Ferlin A; Carli MO; Selice R; Foresta C
Reprod Toxicol; 2006 Aug; 22(2):126-32. PubMed ID: 16781110
[TBL] [Abstract][Full Text] [Related]
16. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
17. Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
Gusdon AM; Malani R; Chen X
J Clin Neurophysiol; 2019 Mar; 36(2):150-154. PubMed ID: 30694943
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Yule SM; Price L; Pearson AD; Boddy AV
Clin Cancer Res; 1997 Nov; 3(11):1985-92. PubMed ID: 9815588
[TBL] [Abstract][Full Text] [Related]
19. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide-induced encephalopathy and movement disorder.
Ames B; Lewis LD; Chaffee S; Kim J; Morse R
Pediatr Blood Cancer; 2010 Apr; 54(4):624-6. PubMed ID: 19953647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
